LAUSR

Tumour necrosis factor-alpha (TNF-α) inhibitors have been successfully used in the treatment of various immune-mediated inflammatory diseases. However, these agents are frequently associated with mucocutaneous adverse effects.1 Anti-TNF-α-induced lupus erythematosus (LE) represents an uncommon adverse effect and has implications on patient management.2 Herein, we report a female patient who developed cutaneous LE after treatment with adalimumab for her rheumatoid arthritis (RA). A woman aged 40 years presented with photosensitivity and painless oral ulcers of 1-month duration. On examination, ill-defined erythema was present over her nose extending to malar area. Well-defined erythematous ulcers were present over buccal mucosae, lips and hard palate (figure 1A,B). Chillblain-like lesions were present over both ears (figure 1C). Her medical history was significant for the presence of RA, for which she had received four doses of …